NO20054640L - Fremgangsmater for behandling av Parkinsons sykdom - Google Patents

Fremgangsmater for behandling av Parkinsons sykdom

Info

Publication number
NO20054640L
NO20054640L NO20054640A NO20054640A NO20054640L NO 20054640 L NO20054640 L NO 20054640L NO 20054640 A NO20054640 A NO 20054640A NO 20054640 A NO20054640 A NO 20054640A NO 20054640 L NO20054640 L NO 20054640L
Authority
NO
Norway
Prior art keywords
disease
parkinson
safinamide
procedures
treatment
Prior art date
Application number
NO20054640A
Other languages
English (en)
Other versions
NO334316B1 (no
NO20054640D0 (no
Inventor
Luca Benatti
Patricia Salvati
Fariello Ruggero
Carlo Cattaneo
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054640(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Publication of NO20054640D0 publication Critical patent/NO20054640D0/no
Publication of NO20054640L publication Critical patent/NO20054640L/no
Publication of NO334316B1 publication Critical patent/NO334316B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ny bruk av safinamid, safinamidderivater og MAO-B-inhibitorer i nye behandlingstyper for Parkinsons sykdom er beskrevet. Mer spesifikt vedrører oppfinnelsen fremgangsmå· ter for behandling av Parkinsons sykdom gjennom administrering av safinamid, et safinamidderivat eller en MAO-Binhibitor, i kombinasjon med andre Parkinsons sykdom-midler eller behandlinger, slik som levodopa/PDI eller dopaminagonister.
NO20054640A 2003-04-11 2005-10-10 Anvendelse av safinamid i kombinasjon med levodopa/PDI for fremstilling av medikamenter til behandling av Parkinsons sykdom NO334316B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46220503P 2003-04-11 2003-04-11
PCT/IB2004/001408 WO2004089353A2 (en) 2003-04-11 2004-04-08 Methods for treatment of parkinson's disease

Publications (3)

Publication Number Publication Date
NO20054640D0 NO20054640D0 (no) 2005-10-10
NO20054640L true NO20054640L (no) 2005-12-09
NO334316B1 NO334316B1 (no) 2014-02-03

Family

ID=33159845

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20054640A NO334316B1 (no) 2003-04-11 2005-10-10 Anvendelse av safinamid i kombinasjon med levodopa/PDI for fremstilling av medikamenter til behandling av Parkinsons sykdom
NO20131417A NO335537B1 (no) 2003-04-11 2013-10-28 Anvendelse av safinamid for fremstilling av medikamenter til behandling av Parkinsons sykdom
NO2015018C NO2015018I1 (no) 2003-04-11 2015-07-23 Safinamid for anvendelse i kombinasjon med levodopa/DPI samt eventuelt med andre PD medisinske produkter for behandling av Parkinsons sykdom

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20131417A NO335537B1 (no) 2003-04-11 2013-10-28 Anvendelse av safinamid for fremstilling av medikamenter til behandling av Parkinsons sykdom
NO2015018C NO2015018I1 (no) 2003-04-11 2015-07-23 Safinamid for anvendelse i kombinasjon med levodopa/DPI samt eventuelt med andre PD medisinske produkter for behandling av Parkinsons sykdom

Country Status (28)

Country Link
US (3) US8283380B2 (no)
EP (2) EP1613296B1 (no)
JP (2) JP2006522800A (no)
KR (2) KR101129015B1 (no)
CN (2) CN102274517B (no)
AR (1) AR044007A1 (no)
AT (1) ATE435012T1 (no)
AU (1) AU2004228782B2 (no)
BR (1) BRPI0409364A (no)
CA (1) CA2523188C (no)
CY (3) CY1109295T1 (no)
DE (1) DE602004021790D1 (no)
DK (2) DK2070526T3 (no)
ES (2) ES2454272T3 (no)
FR (1) FR15C0054I2 (no)
HU (1) HUS1500043I1 (no)
IL (2) IL171331A (no)
LU (1) LU92782I2 (no)
MX (1) MXPA05010873A (no)
NL (1) NL300752I2 (no)
NO (3) NO334316B1 (no)
NZ (1) NZ542910A (no)
PL (2) PL2070526T3 (no)
PT (2) PT1613296E (no)
RU (1) RU2342929C2 (no)
SI (2) SI2070526T1 (no)
TW (1) TWI340640B (no)
WO (1) WO2004089353A2 (no)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
IL160523A0 (en) 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
AU2004266494B2 (en) * 2003-08-25 2010-04-08 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
ATE471147T1 (de) * 2004-09-10 2010-07-15 Newron Pharm Spa Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
EP1954256A2 (en) 2005-11-09 2008-08-13 Torrent Pharmaceuticals Ltd Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
EP1963280B1 (en) * 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
HUE030233T2 (en) 2006-06-19 2017-04-28 Newron Pharm Spa High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
DE102007014947B4 (de) * 2007-03-23 2010-05-27 Axxonis Pharma Ag Stabilisierte wässrige Lösungen von Ergolinverbindungen
JP2010525018A (ja) * 2007-04-24 2010-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物
PT2155663T (pt) 2007-06-15 2018-01-16 Newron Pharm Spa Derivados de 2-[2-(fenil)etilamino]alcanamida substituídos e sua utilização como moduladores dos canais de sódio e/ou de cálcio
GB2453770A (en) * 2007-10-19 2009-04-22 Reckitt Benckiser Healthcare Oral composition comprising a cooling agent
US20090149544A1 (en) * 2007-10-22 2009-06-11 Concert Pharmaceuticals, Inc. Alpha-aminoamide derivatives
CA2936209C (en) 2007-12-11 2020-02-11 Newron Pharmaceuticals S.P.A. Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
BRPI0821026A2 (pt) * 2007-12-19 2015-06-16 Newron Pharmaceutical S P A Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
WO2009122351A2 (en) * 2008-04-01 2009-10-08 Kangwon National University Anti-parkinsonian compounds mppe
EP2285769B1 (en) 2008-06-02 2014-08-13 Generics [UK] Limited A process for the preparation of enantiomerically pure amines
AU2009254929B2 (en) * 2008-06-02 2014-03-13 Generics [Uk] Limited An improved process for the preparation of amines
CN102105169B (zh) * 2008-06-06 2014-09-10 图必制药公司 用于治疗帕金森病的药物组合物
MX2010013766A (es) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
WO2010010138A1 (en) * 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
EP2218444A3 (en) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
CN102048717B (zh) 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
WO2011098456A1 (en) * 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
JP5808392B2 (ja) 2010-04-27 2015-11-10 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法
MX2012012069A (es) 2010-04-30 2012-11-22 Teikoku Pharma Usa Inc Composiciones transdermicas de propinilaminoindan.
KR101853082B1 (ko) 2011-03-24 2018-04-27 테이코쿠 팔마 유에스에이, 인코포레이티드 활성제층 및 활성제 변환층을 포함하는 경피 조성물
US20150031768A1 (en) * 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
EP2744771B1 (en) 2011-08-19 2020-10-21 The Trustees of Princeton University C-halogen bond formation
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
PT2908805T (pt) 2012-10-22 2021-09-10 Civitas Therapeutics Inc Formulações de levodopa para alívio rápido da doença de parkinson
JP6050896B2 (ja) 2012-11-02 2016-12-21 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダン経皮組成物
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
KR20160026897A (ko) 2013-06-27 2016-03-09 세다르스-신나이 메디칼 센터 신경퇴행성 질환의 예방 및 치료를 위한 아드레날린 수용체 길항제
WO2015163840A1 (en) * 2014-04-21 2015-10-29 Civitas Therapeutics, Inc. Rapid relief of motor fluctuations in parkinson's disease
WO2016052928A1 (ko) * 2014-10-02 2016-04-07 한국과학기술연구원 알파-아미노아미드 유도체 화합물 및 이를 포함하는 약학적 조성물
RU2018110580A (ru) * 2015-08-27 2019-09-30 Прекстон Терапьютикс Са Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии
CN109414417A (zh) * 2016-03-17 2019-03-01 约翰·霍普金斯大学 通过paris的法尼基化预防或治疗帕金森症的方法
ITUA20163981A1 (it) 2016-05-31 2017-12-01 Zambon Spa Composizioni farmaceutiche comprendenti safinamide
EP3568082A4 (en) * 2017-01-14 2020-12-09 Neurrx, SPC METHOD OF USE OF HUMAN EXCREMENTS AND SECRETIONS FOR THE EARLY DETECTION OF PARKINSON'S DISEASE
CN109251155A (zh) * 2017-07-14 2019-01-22 广东东阳光药业有限公司 α-氨基酰胺衍生物及其用途
EP3668501A4 (en) * 2017-08-17 2021-03-17 Zi-Qiang Gu MONOAMINE PAMOATE SALTS ANTI-PARKINSON AGENTS, THEIR PREPARATION AND USE
CN111432806A (zh) 2017-11-02 2020-07-17 萨宝公司 包含沙芬酰胺的药物组合物
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
CA3153405A1 (en) * 2019-09-12 2021-03-18 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
LU101477B1 (en) * 2019-11-12 2021-05-14 Univ Luxembourg An inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition
CN110938014A (zh) * 2019-11-28 2020-03-31 岳千奥 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
JP2023504876A (ja) * 2019-12-06 2023-02-07 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 薬物組成物、キット及びその応用
CN110999980A (zh) * 2019-12-19 2020-04-14 新疆石河子职业技术学院（石河子市技工学校） 一种葡萄酒洗浸奶酪加工方法
US20230181508A1 (en) * 2020-08-31 2023-06-15 Purdue Pharma L.P. Compositions and methods for levodopa delivery
CN117222355A (zh) * 2021-03-08 2023-12-12 普罗塞纳生物科学有限公司 帕金森病的治疗
KR102790040B1 (ko) * 2021-06-24 2025-04-01 연세대학교 산학협력단 도파민 미모톱 기능 합성 펩티드 및 이를 포함하는 mao-b 억제제

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4049663A (en) 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4935429A (en) 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
ES2042520T3 (es) * 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
EP0331620B1 (de) 1988-03-01 1993-08-11 Birkmayer, Walther, Prof. Dr. Mittel zur Behandlung des Parkinson-Syndroms
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en) 1990-12-27 1996-03-26 Relin; Arkadi Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
MX9709112A (es) * 1995-05-26 1998-02-28 Pfizer Combinacion para el tratamiento de parkinsonismo que contienen antagonistas selectivos de n-metil-d-aspartato.
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

Also Published As

Publication number Publication date
US8283380B2 (en) 2012-10-09
TW200505423A (en) 2005-02-16
DK2070526T3 (da) 2014-03-24
CY2015025I1 (el) 2016-04-13
EP1613296B1 (en) 2009-07-01
NZ542910A (en) 2007-10-26
EP2070526A1 (en) 2009-06-17
CN102274517A (zh) 2011-12-14
KR20110070929A (ko) 2011-06-24
CA2523188A1 (en) 2004-10-21
IL216403A0 (en) 2011-12-29
LU92782I2 (fr) 2015-09-22
CN1771030A (zh) 2006-05-10
IL216403A (en) 2015-01-29
NO20131417L (no) 2005-12-09
NO2015018I1 (no) 2015-08-03
NO334316B1 (no) 2014-02-03
RU2005131422A (ru) 2006-04-27
WO2004089353A3 (en) 2004-12-16
AR044007A1 (es) 2005-08-24
EP1613296A2 (en) 2006-01-11
MXPA05010873A (es) 2006-03-21
CA2523188C (en) 2012-09-25
PT2070526E (pt) 2014-03-31
FR15C0054I2 (fr) 2018-01-26
AU2004228782A1 (en) 2004-10-21
AU2004228782B2 (en) 2010-05-20
US9492410B2 (en) 2016-11-15
BRPI0409364A (pt) 2006-04-25
US20150150833A1 (en) 2015-06-04
IL171331A (en) 2012-03-29
US20070093495A1 (en) 2007-04-26
DK1613296T3 (da) 2009-10-05
EP2070526B1 (en) 2014-02-26
TWI340640B (en) 2011-04-21
KR20060010745A (ko) 2006-02-02
PL1613296T3 (pl) 2009-12-31
CY1109295T1 (el) 2014-07-02
CY2015025I2 (el) 2016-04-13
PL2070526T3 (pl) 2014-08-29
US20130053368A1 (en) 2013-02-28
SI2070526T1 (sl) 2014-05-30
JP2006522800A (ja) 2006-10-05
PT1613296E (pt) 2009-07-30
NO335537B1 (no) 2014-12-22
NO2015018I2 (no) 2015-07-23
JP2013067647A (ja) 2013-04-18
KR101129015B1 (ko) 2012-04-20
WO2004089353A2 (en) 2004-10-21
CY1115286T1 (el) 2017-01-04
DE602004021790D1 (de) 2009-08-13
FR15C0054I1 (fr) 2015-11-09
HUS1500043I1 (hu) 2018-11-28
ES2454272T3 (es) 2014-04-10
ES2326373T3 (es) 2009-10-08
US8901176B2 (en) 2014-12-02
NL300752I2 (no) 2016-07-05
WO2004089353A8 (en) 2005-09-01
SI1613296T1 (sl) 2009-10-31
CN102274517B (zh) 2018-08-31
ATE435012T1 (de) 2009-07-15
RU2342929C2 (ru) 2009-01-10
NO20054640D0 (no) 2005-10-10

Similar Documents

Publication Publication Date Title
NO20054640L (no) Fremgangsmater for behandling av Parkinsons sykdom
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
DK1656122T4 (da) Transdermale lægemiddeltilberedninger med kombinationer af aktive stoffer til behandling af Parkinsons syge
BR0306872A (pt) Composições e métodos de tratamento envolvendo agonistas do receptor-gama ativado pelo proliferador de peroxissoma e inibidores seletivos da ciclooxigenase-2
EA200501700A1 (ru) Применение эффектов глутаминил- и глутаматциклаз
TR200201004T2 (tr) Monoamin reuptake önleyicileri olarak biaril eter türevleri
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
NO20064792L (no) Anvendelse av rotigotin til behandling og forbinding av Parkinsons pluss syndrom.
NO20033665L (no) Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
BRPI1008727B8 (pt) derivado de azol substituído, inibidor de monoamina-oxidase b (maob) e composição farmacêutica contendo os derivadospara o tratamento de doença de parkinson
ZA202212095B (en) Il4i1 inhibitors and methods of use
ATE413177T1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
NO20052359L (no) Karbostyilderivater og serotonin reopptaks inhibitorer for behandling av humor forsyrrelser
IS7517A (is) Efnasambönd sem nýtast í meðferð við miltisbrandiog hindra banvænan þátt
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
WO2004052858A3 (en) Inhibitors of monoamine uptake
AR039977A1 (es) Composicion a base de diclofenac para el tratamiento topico de afecciones de la cavidad orofaringea
MXPA05006408A (es) Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos.
EP4234022A3 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
ATE429216T1 (de) Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
SE0203349D0 (sv) New use
BR0212991A (pt) Métodos de tratamento oftalmológico utilizando inibidores seletivos de inos
TW200504016A (en) Inhibitors of monoamine uptake

Legal Events

Date Code Title Description
SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: SAFINAMID FOR ANVENDELSE I KOMBINASJON MED LEVODOPA/DPI SAMT EVENTUELT MED ANDRE PD MEDISINSKE PRODUKTER FOR BEHANDLING AV PARKINSONS SYKDOM; EU/1/14/984

Spc suppl protection certif: 2015018

Filing date: 20150723